
Vertex Pharmaceuticals Incorporated
-3.83 %
13.42 %
Yet to be announced
Company Overview
Vertex Pharmaceuticals Incorporated is a global biotechnology company that develops and commercializes medicines to treat serious diseases. The company focuses primarily on developing innovative therapies for cystic fibrosis (CF) and has expanded its pipeline to include treatments for other serious diseases like sickle cell disease, beta thalassemia, type 1 diabetes, and pain management.
Revenue Sources
PassVertex's revenue primarily comes from the sale of medicines for treating serious diseases, particularly cystic fibrosis. The company's main products include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. None of these products or the company's research activities involve haram elements such as alcohol, pork derivatives, or gambling.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $2.77b | $1.66b | - | $7.5m | 0.00% | 0.45% |
June 30, 2024 | $2.65b | $6.17b | - | $9.9m | 0.00% | 0.16% |
March 31, 2024 | $2.69b | $1.56b | - | $10.4m | 0.00% | 0.67% |
Dec. 31, 2023 | $2.52b | $1.54b | - | $10.6m | 0.00% | 0.69% |
Based on the financial data from the last four quarters, Vertex's interest expense relative to total expenses has been consistently minimal. The interest expense ratios for the most recent quarters were well below the 5% threshold that would indicate material reliance on interest-bearing debt.
Operational Ethics
PassAfter reviewing Vertex's global operations and partnerships through SEC filings and company disclosures, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company maintains research and commercial operations primarily in North America and Europe.
Login to join the discussion